FDA Approves Tysabri To Treat Moderate-To-Severe Crohn's Disease

Armen Hareyan's picture
Advertisement

FDA has approved Tysabri (natalizumab) for the treatment of moderate-to-severe Crohn's disease in patients with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional Crohn's disease therapies. Crohn's disease patients using the drug must be enrolled in a special restricted distribution program called the Crohn's Disease

Advertisement